Compare RNA & MMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | MMT |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 244.9M |
| IPO Year | 2025 | N/A |
| Metric | RNA | MMT |
|---|---|---|
| Price | $9.03 | $4.35 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $69.26 | N/A |
| AVG Volume (30 Days) | ★ 296.3K | 276.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.58% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | $14.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.44 | $4.30 |
| 52 Week High | $73.06 | $4.85 |
| Indicator | RNA | MMT |
|---|---|---|
| Relative Strength Index (RSI) | 25.37 | 41.03 |
| Support Level | N/A | N/A |
| Resistance Level | $14.39 | $4.71 |
| Average True Range (ATR) | 0.74 | 0.06 |
| MACD | -0.42 | -0.01 |
| Stochastic Oscillator | 0.18 | 21.05 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Aberdeen Multi-Market Income Fund's investment objective is to seek high current income, but it may also consider capital appreciation.